Plasmodium vivax vaccine: What is the best way to go?
Frontiers in Immunology · 16.01.2023 · 13
DOI: 10.3389/fimmu.2022.910236 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 16.01.2023. Verfasst von Gisele Tatiane Soares da Veiga und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Apicomplexan Parasites Research, Carlos Chagas Institute, Oswaldo Cruz Foundation (FIOCRUZ), Curitiba, Brazil. Hauptthemen laut MEDLINE: Malaria, Vivax, Malaria, Malaria Vaccines. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 251 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Malaria is one of the most devastating human infectious diseases caused by Plasmodium spp. parasites. A search for an effective and safe vaccine is the main challenge for its eradication. Plasmodium vivax is the second most prevalent Plasmodium species and the most geographically distributed parasite and has been neglected for decades. This has a massive gap in knowledge and consequently in the development of vaccines. The most significant difficulties in obtaining a vaccine against P. vivax are the high genetic diversity and the extremely complex life cycle. Due to its complexity, studies have evaluated P. vivax antigens from different stages as potential targets for an effective vaccine. Therefore, the main vaccine candidates are grouped into preerythrocytic stage vaccines, blood-stage vaccines, and transmission-blocking vaccines. This review aims to support future investigations by presenting the main findings of vivax malaria vaccines to date. There are only a few P. vivax vaccines in clinical trials, and thus far, the best protective efficacy was a vaccine formulated with synthetic peptide from a circumsporozoite protein and Montanide ISA-51 as an adjuvant with 54.5% efficacy in a phase IIa study. In addition, the majority of P. vivax antigen candidates are polymorphic, induce strain-specific and heterogeneous immunity and provide only partial protection. Nevertheless, immunization with recombinant proteins and multiantigen vaccines have shown promising results and have emerged as excellent strategies. However, more studies are necessary to assess the ideal vaccine combination and test it in clinical trials. Developing a safe and effective vaccine against vivax malaria is essential for controlling and eliminating the disease. Therefore, it is necessary to determine what is already known to propose and identify new candidates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Apicomplexan Parasites Research, Carlos Chagas Institute, Oswaldo Cruz Foundation (FIOCRUZ), Curitiba, Brazil.
- Nitrogen Fixation Laboratory, Department of Biochemistry and Molecular Biology, Federal University of Paraná (UFPR), Curitiba, Brazil.
- Biomedical Sciences Course, Educational Union of Cascavel (UNIVEL), Cascavel, Brazil.
Zitieren
APA
da Veiga, G. T. S., Moriggi, M. R., Vettorazzi, J. F., Müller-Santos, M., & Albrecht, L. (2023). Plasmodium vivax vaccine: What is the best way to go?. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.910236
Vancouver
da Veiga GTS, Moriggi MR, Vettorazzi JF, Müller-Santos M, Albrecht L. Plasmodium vivax vaccine: What is the best way to go?. Frontiers in Immunology. 2023;13. doi:10.3389/fimmu.2022.910236
BibTeX
@article{daVeiga2023,
author = {da Veiga, Gisele Tatiane Soares and Moriggi, Matheus Ribeiro and Vettorazzi, Jean Franciesco and Müller-Santos, Marcelo and Albrecht, Letusa},
title = {Plasmodium vivax vaccine: What is the best way to go?},
journal = {Frontiers in Immunology},
year = {2023},
volume = {13},
doi = {10.3389/fimmu.2022.910236}
}
EUVIMED